Hostname: page-component-745bb68f8f-b6zl4 Total loading time: 0 Render date: 2025-01-15T00:48:41.998Z Has data issue: false hasContentIssue false
  • English
  • Français

Progressive Supranuclear Palsy

Published online by Cambridge University Press:  05 January 2016

Joseph Jankovic  and
Haydee Rohaidy
Joseph Jankovic*
Affiliation:
Department of Neurology, Baylor College of Medicine, Houston, Texas
Haydee Rohaidy
Affiliation:
Department of Neurology, Baylor College of Medicine, Houston, Texas
*
Department of Neurology, Baylor College of Medicine, 1 Baylor Plaz, Houston, Texas 77030 U.S.A.
Rights & Permissions [Opens in a new window]

Abstract:

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Progressive supranuclear palsy (PSP) was first recognized as a distinct morbid entity by Richardson, Steele and Olszewski a quarter century ago. Subsequent experience has confirmed and extended their original observations. PSP has become familiar as a chronic progressive disorder with extrapyramidal rigidity, bradykinesia, gait impairment, bulbar palsy, dementia and a characteristic supranuclear ophthalmoplegia. It is an important cause of parkinsonism. Its etiology remains obscure. Familial concentrations have not been observed.

Some cases exhibit no oculomotor dysfunction. Dementia is usually mild. Recent neuropsychological studies have defined features consistent with frontal lobe cortical dysfunction. Seizures and paroxysmal EEG activity may occur.

CT and MRI scans show midbrain atrophy early and later atrophy of the pontine and midbrain tegmentum and the frontal and temporal lobes. PET scans have shown frontal hypometabolism and loss of striatal D-2 dopamine receptors. Postmortem studies have documented involvment of both dopaminergic and cholinergic systems. Treatment remains palliative and unsatisfactory.

Type
Research Article
Information
Canadian Journal of Neurological Sciences , Volume 14 , Issue S3 , August 1987 , pp. 547 - 554
Copyright
Copyright © Canadian Neurological Sciences Federation 1987

References

REFERENCES

1.Richardson, JC, Steele, JC, Olszewski, J.Supranuclear opthalmoplegia, pseudobulbar palsy, nuchal dystonia and dementia: a clinical report on eight cases of “heterogenous system degeneration”. Trans Am Neurol Assoc 1963; 88: 25–27.Google Scholar
2.Verhaart, WJC.Degeneration of the brain stem and the cerebellum: an example of heterogenous systemic degeneration of the central nervous system. J Neuropath Exp Neurol 1958; 17: 382–391.CrossRefGoogle ScholarPubMed
3.Chavany, JA, van Bogaert, L, Godlewski, S.Sur un syndrome de rigidité a predominance axiale avec perturbation des automatismes oculo-palpebral d’origine encephalitique. Presse Med 1951; 59: 958–962.Google Scholar
4.Neumann, MA.Heterogenous system degeneration with particular involvement of reticular substance: correlation with neurologic disorders and the concept of Creutzfeld-Jacob disease. J Neuropath Exp Neurol 1961; 20: 316.Google Scholar
5.Steele, JC, Richardson, JC, Olszewski, J.Progressive supranuclear palsy. Arch Neurol (Chicago) 1964; 10: 333–359.Google Scholar
6.Pfaffenbach, DD, Layton, DD, Kearns, TP.Ocular manifestations in progressive supranuclear palsy. Am J Ophthalmol 1972, 74: 1179–1184.CrossRefGoogle ScholarPubMed
7.Kristensen, MO.Progressive supranuclear palsy - 20 years later. Acta Neurol Scand. 1985; 71: 177–189.CrossRefGoogle ScholarPubMed
8.Golbe, LI, Davis, PH, Schoenberg, BS, Duvoisin, RC.The natural history and prevalence of progressive supranuclear palsy. Neurology 1987; 37: 259 [abstract].Google Scholar
9.Maher, ER, Lees, AJ.The clinical features and natural history of the Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). Neurology 1986; 36: 1005–1008.CrossRefGoogle ScholarPubMed
10.Steele, JC.Progressive supranuclear palsy. Brain 1972; 95: 693–704.Google ScholarPubMed
11.Steele, JC.Progressive supranuclear palsy. In: Vinken, P, Bruyn, H, eds. Handbook of Clinical Neurology Vol 22, System Disorders and Atrophies. Amsterdam, Elsevier 1975; 217–229.Google Scholar
12.Nuwer, MR.Progressive supranuclear palsy despite normal eye movements. Arch Neurol 1981; 38: 784–785.CrossRefGoogle ScholarPubMed
13.Perkin, GD, Lees, AJ, Stern, GM, Kocen, RS.Problems in the diagnosis of progressive supranuclear palsy. Can J Neurol Sci 1978, 5: 167–173.CrossRefGoogle ScholarPubMed
14.Dubas, F, Gray, F, Escourelle, R.Maladie de Steele-Richardson-Olszewski sans ophthalmoplegic. Rev Neurol (Paris) 1983; 139: 497–516.Google Scholar
15.Davis, PH, Bergeron, C, McLachlan, DR.Atypical presentation of progressive supranuclear palsy. Ann Neurol 1985; 17: 373–343.CrossRefGoogle ScholarPubMed
16.Probst, A, Dufresne, JJ.Paralysie supranucleaire progressive ou dystonie oculo-facio-cervicale. Schwiez Arch Neurol Neurochir Psychiatr 1975; 116: 107–134.Google Scholar
17.Jellinger, K, Riederer, P, Tomonga, M.Progressive supranuclear palsy: clinicopathological and biochemical studies. J Neural Trans Suppl 1980; 16: 111–128.Google Scholar
18.Brusa, A.Dégénérescence plurisystematisee du nevraxe, de charactere sporadique, a debut tardif et evolution subaigu. Rev Neurol (Paris) 1961; 104: 412–429.Google Scholar
19.Kurihara, T, Landau, WM, Torack, RM.Progressive supranuclear palsy with action myoclonus, seizures. Neurology 1974; 24: 219–223.CrossRefGoogle ScholarPubMed
20.Scott, D.Progressive supranuclear palsy in a Navaho. Rocky Mt Med J 1970; 67: 335–37.Google Scholar
21.Leygonie, F, Thomas, J, Deghos, J, et al. Troubles de sommeil dans la maladie de Steele-Richardson: etude polygraphique de 3 cas. Rev Neurol (Paris) 1976; 132: 125–136.Google Scholar
22.Gross, RA, Spehlmann, R, Daniels, JC.Sleep disturbances in progressive supranuclear palsy. Electroencephalogr Clin Neurophysiol 1978; 45: 125–136.CrossRefGoogle ScholarPubMed
23.Jackson, JA, Jankovic, J, Ford, J.Progressive supranuclear palsy: clinical features in 16 patients. Ann Neurol 1983; 13: 273–278.CrossRefGoogle ScholarPubMed
24.Stern, M.Personal communication. 1987.Google Scholar
25.Agid, Y, Javoy-Agid, F, Ruberg, M, et al. Progressive supranuclear palsy: Anatomoclinical and biochemical considerations. Adv Neurol 1986, 45: 191–206.Google Scholar
26.Davis, PH, Golbe, LI, Duvoisin, RC, Schoenberg, BS.Risk factors for progressive supranuclear palsy. [Abstract] Neurology, 1987; 37: 121.Google Scholar
27.Newman, N, Gay, AJ, Stroud, MH, Brooks, J.Defective rapid eye movements in progressive supranuclear palsy: an ocular electromyographic study. Brain 1970; 93: 775–784.CrossRefGoogle ScholarPubMed
28.Dix, MR, Harrison, MJG, Lewis, PD.Progressive supranuclear palsy: the Steele-Richardson-Olszewski syndrome: a report of nine cases with particular reference to the mechanism of the oculomotor disorder. J Neurol Sci 1971; 13: 2377–256.CrossRefGoogle Scholar
29.Troost, BT, Daroff, RB.The ocular motor defects in progressive supranuclear palsy. Ann Neurol 1977; 2: 397–403.CrossRefGoogle ScholarPubMed
30.Golbe, LI, Davis, PH, Lepore, FE, et al. The range of eyelid abnormalities in progressive supranuclear palsy. [Abstract] Neurology 1987; 37: 259.Google Scholar
31.Karson, CN.Spontaneous eye-blink rate and dopaminergic systems. Brain 1983; 106: 643–653.CrossRefGoogle ScholarPubMed
32.Lepore, FE, Duvoisin, RC.“Apraxia” of eyelid opening: an involuntary levator inhibition. Neurology 1985; 35: 423–427.CrossRefGoogle ScholarPubMed
33.Goldstein, JE, Cogan, DG.Apraxia of lid-opening. Arch Ophthalmol. 1965, 73: 155–159.CrossRefGoogle ScholarPubMed
34.Riese, W.Apraxie der lidoffnung(analyse einer bewegungsstorung). J Psychol Neurol Lpz 1930; 40: 347–355.Google Scholar
35.Leigh, RJ, Zee, DS.The neurology of eye movements. Philadelphia, FA Davis 1983; 49–52.Google Scholar
36.Schonfeld, SM, Safer, J, Sage, JI, et al. Computed tomograpic findings in progressive supranuclear palsy. Movement Disorders 1987; (in press).CrossRefGoogle Scholar
37.Guiloff, RJ, George, RJ, Marsden, CD.Reversible supranuclear opthalmoplegia associated with parkinsonism. J Neurol Neurosurg Psych 1980; 43: 552–554.CrossRefGoogle Scholar
38.Lepore, FE.Disorders of ocular motility in the olivopontocerebellar atrophies. Adv Neurol 1984; 41: 97–103.Google ScholarPubMed
39.Duvoisin, RC.Olivopontocerebellar atrophy. In: Fahn, S, Marsden, D, eds. Movement Disorders 11, London, Butterworthés 1987; 249–269.Google Scholar
40.Nygaard, T, Duvoisin, RC, Manocha, M, Chokroverty, S.Epileptic seizures in progressive supranuclear palsy. Neurology 1986; 36 (Suppl 1): 341.Google Scholar
41.Frigyesi, TL.Parkinsonism and epilepsy. In: Messiha, FS, Kenny, AD, eds. Parkinson’s disease, New York, Plenum Press 1977: 63–102.CrossRefGoogle Scholar
42.Dubinsky, RM, Jankovic, J.Progressive supranuclear palsy: relationship to a multi-infarct state and cerebral amyloid angiopathy. Neurology 1987; 37: 570–576.CrossRefGoogle Scholar
43.Bentson, JR, Keesey, JC.Pneumoencephalography of progressive supranuclear palsy. Radiology 1974: 113: 89–94.CrossRefGoogle ScholarPubMed
44.Ambrosetto, P, Michelucci, R, Forti, A, Tassinari, CA.CT findings in progressive supranuclear palsy. J Computer Assisted Tomography 1984; 8: 406–409.CrossRefGoogle ScholarPubMed
45.Haldeman, S, Goldman, JW, Hyde, J, Pribram, HFW.Progressive supranuclear palsy, computed tomography and response to antiparkinsonian drugs. Neurology 1981; 31: 442–445.CrossRefGoogle ScholarPubMed
46.Drayer, BP, Olanow, W, Burger, P, et al. Parkinson plus syndrome: diagnosis using high field MF imaging of brain iron. Radiology 1986; 159: 493–498.CrossRefGoogle Scholar
47.D’Antona, R, Baron, JC, Samson, Y, et al. Subcortical dementia: frontal cortex hypometabolism detected by positron tomography in patients with progressive supranuclear palsy. Brain 1985; 108: 785–799.CrossRefGoogle ScholarPubMed
48.Foster, NL, Gilman, S, Berent, S, Hichwa, RD.Distinctive patterns of cerebral glucose metabolism in progressive supranuclear palsy and Alzheimer’s disease studied with positron emission tomography. [Abstract] Neurology 1986; 36 (Suppl 1): 338.Google Scholar
49.Baron, JC, Maziere, B, Loc’h, C, et al. Progressive supranuclear palsy : Loss of striatal dopamine receptors demonstrated in vivo by positron tomography. Lancet 1985; 1: 1163–1164.CrossRefGoogle ScholarPubMed
50.Martin, WRW.Cerebral glucose and dopa metabolism in movement disorders. Can J Neurol Sci 1987; 14 (suppl): 448–451 [this issue].CrossRefGoogle ScholarPubMed
51.Maher, ER, Smith, EM, Lees, AJ.Cognitive deficits in the Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). J Neurol Neurosurg Psychiat 1985; 48: 1234–1239.CrossRefGoogle ScholarPubMed
52.Kimura, D, Barnett, HJM, Burkhart, G.The psychological test pattern in progressive supranuclear palsy. Neuropsychologia 1981; 19: 301–305.CrossRefGoogle ScholarPubMed
53.Fisk, JD, Goodale, MA, Burkhart, G, Barnett, HJM.Progressive supranuclear palsy: the relationship between ocular motor dysfunction and psychological test performance. Neurology 1982; 32: 698–705.CrossRefGoogle ScholarPubMed
54.Pirozzolo, FJ, Jankovic, J, Levy, JK.Progressive supranuclear palsy: are cognitive and motor deficits related? Neurology 1986; 36 (Suppl 1): 308.Google Scholar
55.Albert, LM, Feldman, RG, Willis, AL.The “subcortical dementia” of progressive supranuclear palsy. J Neurol Neurosurg Psychiat 1974; 37: 121–130.CrossRefGoogle Scholar
56.Mayeux, R, Stern, Y, Rosen, J, Benson, DF.Is “subcortical dementia” a recognizable clinical entity? Ann Neurol 1983; 14: 278–283.CrossRefGoogle Scholar
57.Cambier, J, Masson, M, Viader, F, et al. Le syndrome frontal de paralysie supranucleaire progressive. Rev Neurol (Paris) 1985; 141: 528–536.Google Scholar
58.Pillon, B, Dubois, B, Hermitte, F, Agid, Y.Heterogeneity of cognitive impairment in progressive supranuclear palsy, Parkinson’s disease and Alzheimer’s disease. Neurology 1986; 36: 1179–1185.CrossRefGoogle ScholarPubMed
59.Ishino, H, Otsuki, S.Frequency of Alzheimer’s neurofibrillary tangles in the cerebral cortex in progressive supranuclear palsy. J Neurol Sci 1976; 28: 309–316.CrossRefGoogle ScholarPubMed
60.Behrman, S, Carroll, JD, Janota, I, Matthews, WB.Progressive supranuclear palsy: clinico-pathological study of four cases. Brain 1969; 92: 663–678.CrossRefGoogle ScholarPubMed
61.Jellinger, K.Progressive supranuclear palsy (subcortical argyrophilic dystrophy). Acta neuropathol (Berlin) 1971; 19: 347–352.Google Scholar
62.Yagashita, S, ltoh, Y, Amano, N, et al. Ultrastructure of neurofibrillary tangles in progressive supranuclear palsy. Acta Neuro-pathologica (Berlin) 1979; 48: 27–30.Google Scholar
63.Powell, HC, London, GW, Lampert, PW.Neurofibrillary tangles in progressive supranuclear palsy: electron microscopic observations. J Neuropath Exp Neurol 1974; 33: 98–106.CrossRefGoogle ScholarPubMed
64.Ishino, H, Higashi, H, Kuroda, S, et al. Motor nuclear involvement in progressive supranuclear palsy. J Neurol Sci 1974; 22: 235–244.CrossRefGoogle ScholarPubMed
65.Blumenthal, H, Miller, C.Motor nuclear involvement in progressive supranuclear palsy. Arch Neurol 1969; 220: 362–367.CrossRefGoogle Scholar
66.Antunes, JL, Yahr, MD, Duvoisin, RC.Progressive supranuclear palsy: a clinical, pathological and biochemical study. [Abstract] Neurology 1972; 22: 445.Google Scholar
67.Roy, S, Datta, CK, Hirano, A, et al. Electron microscopic study of neurofibrillary tangles in Steele-Richardson-Olszewski syndrome. Acta Neuropathol (Berlin) 1974; 29: 175–179.Google Scholar
68.Bugiani, O, Mancardi, GL, Brusa, A, Ederli, A.The fine structure of subcortical neurofibrillary tangles in progressive supranuclear palsy. Acta Neuropathol (Berlin) 1979; 45: 147–152.Google Scholar
69.Tomonaga, M.Ultrastructure of neurofibrillary tangles in progressive supranuclear palsy. Acta neuropathol (Berlin) 1977; 37: 1771–1781.Google Scholar
70.Ghatak, NR, Nochlin, D, Hadfield, MG.Neurofibrillary pathology in progressive supranuclear palsy. Acta Neuropathol (Berlin) 1980; 52: 73–76.Google Scholar
71.Yen, S-H, Houroupian, DS, Terry, RD.Immunocytochemical comparison of neurofibrillary tangles in senile dementia of Alzheimer type, progressive supranuclear palsy and postencephalitic parkinsonism. Ann Neurol 1983; 13: 172–175.CrossRefGoogle ScholarPubMed
72.Morariu, MA.Progressive supranuclear palsy and normal pressure hydrocephalus. Neurology 1979; 29: 1544–1546.CrossRefGoogle ScholarPubMed
73.Papeschi, R, Molina-Negro, P, Sourkes, TL, Erba, G.The concentration of homovanillic and 5-hydroxyindoleacetic acids in ventricular and lumbar CSF. Neurology 1972; 22: 1151–1159.CrossRefGoogle ScholarPubMed
74.Mendel, JR, Chase, TN, Engel, WK.Modification by l-dopaofacase of progressive supranuclear palsy. Lancet 1970; 1: 593–594.CrossRefGoogle Scholar
75.Klawans, HL, Ringel, SP.Observations on the efficacy of l-dopa in progressive supranuclear palsy. Eur Neurol 1971; 5: 115–129.CrossRefGoogle ScholarPubMed
76.Ruberg, M, Javoy-Agid, F, Hirsch, E, et al. Dopaminergic and cholinergic lesions in progressive supranuclear palsy. Ann Neurol 1985; 18: 523–529.CrossRefGoogle ScholarPubMed
77.Kish, SJ, Chang, LJ, Mirchandani, L, et al. Progressive supranuclear palsy: relationship between extrapyramidal disturbances, dementia and brain neurotransmitter markers. Ann Neurol 1985; 18: 530–536.CrossRefGoogle ScholarPubMed
78.Bokobza, B, Ruberg, M, Scatton, B, et al. 3H-spiperone binding, dopamine and HVA concentrations in Parkinson’s disease and supranuclear palsy. Eur J Pharmacol 1984; 99: 167–175.CrossRefGoogle Scholar
79.Young, AB.Editorial. Progressive supranuclear palsy: postmortem chemical analysis. Ann Neurol 1985; 18: 521–522.CrossRefGoogle ScholarPubMed
80.Janati, A, Appel, A.Psychiatric aspects of progressive supranuclear palsy. J Nerv Ment Dis 1984; 172: 85–89.CrossRefGoogle ScholarPubMed
81.Baron, JC, Maziere, B, Loc’h, C, et al. Loss of striatal 76Br-bromspirone binding sites demonstrated by positron emission tomography in progressive supranuclear palsy. J Cerebral Blood Flow and Metabolism 1986; 6: 131–136.CrossRefGoogle ScholarPubMed
82.Neophytides, A, Lieberman, AN, Goldstein, M, et al. The use of lisuride, a potent dopamine and serotonin agonist in the treatment of progressive supranuclear palsy. J Neurol Neurosurg Psychiat 1982; 45: 261–263.CrossRefGoogle ScholarPubMed
83.Rafal, RD, Grimm, RJ.Progressive supranuclear palsy: functional analysis of the response to methysergide and antiparkinsonian agents. Neurology 1981; 31: 1507–1518.CrossRefGoogle ScholarPubMed
84.Kvale, JN.Amitriptyline in the management of progressive supranuclear palsy. Arch Neurol 1982; 39: 387–388.CrossRefGoogle ScholarPubMed
85.Newman, GC.Treatment of progressive supranuclear palsy with tricyclic antidepressants. Neurology 35; 35: 1189–1193.CrossRefGoogle Scholar
86.Schiffer, RB, Herndon, RM, Rudick, RA.Treatment of pathologic laughing and weeping with amitriptyline. New Eng J Med 1985; 312: 1480–1482.CrossRefGoogle ScholarPubMed